{"id":357380,"date":"2025-08-29T10:27:58","date_gmt":"2025-08-29T10:27:58","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-celcuity\/"},"modified":"2025-08-29T10:27:58","modified_gmt":"2025-08-29T10:27:58","slug":"how-to-buy-celcuity","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celcuity\/","title":{"rendered":"Celcuity Inc. (CELC) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Celcuity Inc. (CELC) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334090,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-357380","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Celcuity Inc. (CELC) Hisseleri Nas\u0131l Al\u0131n\u0131r - Celcuity Inc. (CELC) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Celcuity Inc. (CELC) Hisseleri Nas\u0131l Al\u0131n\u0131r - Celcuity Inc. (CELC) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Celcuity Inc. (CELC) hisseleri nas\u0131l al\u0131n\u0131r ve bu umut vadeden biyoteknoloji hissesine nas\u0131l yat\u0131r\u0131m yap\u0131l\u0131r \u00f6\u011frenin. G\u00fcncel fiyat, FDA haberlerinin etkisi ve 2025 i\u00e7in ad\u0131m ad\u0131m yat\u0131r\u0131m stratejilerini ke\u015ffedin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Celcuity Inc. (CELC) hisseleri nas\u0131l al\u0131n\u0131r ve bu umut vadeden biyoteknoloji hissesine nas\u0131l yat\u0131r\u0131m yap\u0131l\u0131r \u00f6\u011frenin. G\u00fcncel fiyat, FDA haberlerinin etkisi ve 2025 i\u00e7in ad\u0131m ad\u0131m yat\u0131r\u0131m stratejilerini ke\u015ffedin."},"intro":"Kanser tedavisinde \u00e7\u0131\u011f\u0131r a\u00e7an bir biyoteknoloji \u015firketine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Celcuity Inc. (CELC), \u00e7\u0131\u011f\u0131r a\u00e7an meme kanseri tedavisi gedatolisib ile dikkat \u00e7ekiyor. Son FDA geli\u015fmeleri ve patlay\u0131c\u0131 hisse performans\u0131yla, bu t\u0131bbi devrime kat\u0131lmak i\u00e7in f\u0131rsat\u0131n\u0131z olabilir. G\u00fcncel fiyatland\u0131rmadan ak\u0131ll\u0131 giri\u015f stratejilerine kadar her \u015feyi detayland\u0131raca\u011f\u0131z.","intro_source":{"label":"Intro","type":"text","formatted_value":"Kanser tedavisinde \u00e7\u0131\u011f\u0131r a\u00e7an bir biyoteknoloji \u015firketine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Celcuity Inc. (CELC), \u00e7\u0131\u011f\u0131r a\u00e7an meme kanseri tedavisi gedatolisib ile dikkat \u00e7ekiyor. Son FDA geli\u015fmeleri ve patlay\u0131c\u0131 hisse performans\u0131yla, bu t\u0131bbi devrime kat\u0131lmak i\u00e7in f\u0131rsat\u0131n\u0131z olabilir. G\u00fcncel fiyatland\u0131rmadan ak\u0131ll\u0131 giri\u015f stratejilerine kadar her \u015feyi detayland\u0131raca\u011f\u0131z."},"body_html":"<h2>\ud83d\udcc8 G\u00fcncel Hisse Fiyat\u0131 ve Kritik Tarihler<\/h2> <p>29 A\u011fustos 2025 itibar\u0131yla Celcuity Inc. (CELC), NASDAQ'da <strong>54,60 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>13 Kas\u0131m 2025<\/strong> kesinlikle kritik\u2014Celcuity'nin 3. \u00e7eyrek kazan\u00e7lar\u0131n\u0131 a\u00e7\u0131klayaca\u011f\u0131 tarih. Tarihsel olarak, bu raporlar fiyatlar\u0131 dramatik \u015fekilde hareket ettirmi\u015ftir.<\/p> <p><strong>A\u011fustos 2025'te FDA Haberlerinin CELC Hissesini Nas\u0131l Hareket Ettirdi\u011fi<\/strong><br\/> Gedatolisib'in Yeni \u0130la\u00e7 Ba\u015fvurusunun FDA taraf\u0131ndan kabul edilmesi b\u00fcy\u00fck yank\u0131 yaratt\u0131. 28 A\u011fustos 2025'te CELC, <strong>%10,69 art\u0131\u015fla 55,30 $<\/strong> seviyesine y\u00fckseldi ve 52 haftal\u0131k en y\u00fcksek seviye olan 55,44 $'a ula\u015ft\u0131 (<a href=\"https:\/\/www.ainvest.com\/news\/celcuity-soars-9-6-record-high-analysts-split-sustainability-2508\/\">AInvest Raporu<\/a>). Bu sadece s\u0131radan bir s\u0131\u00e7rama de\u011fildi\u2014yat\u0131r\u0131mc\u0131lar\u0131 heyecanland\u0131ran <strong>y\u0131lba\u015f\u0131ndan bu yana %210'luk kazanc\u0131n<\/strong> doruk noktas\u0131yd\u0131.<\/p>  [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu: \u0130stikrarl\u0131dan Muhte\u015feme<\/h2> <p>Celcuity'nin hissesi \u015eubat 2025'ten beri muazzam bir y\u00fckseli\u015f g\u00f6sterdi:<\/p> <ul> <li><strong>\u015eubat 2025<\/strong>: ~15-18 $ (istikrarl\u0131 klinik ilerleme)<\/li> <li><strong>Nisan 2025<\/strong>: ~22-25 $ (Faz 3 veri beklentisi)<\/li> <li><strong>Haziran 2025<\/strong>: ~35-40 $ (pozitif deneme s\u00f6ylentileri)<\/li> <li><strong>Temmuz 2025<\/strong>: 13,59 $'dan 50+ $ aral\u0131\u011f\u0131na (patlay\u0131c\u0131 b\u00fcy\u00fcme)<\/li> <li><strong>A\u011fustos 2025<\/strong>: 49,96 $'dan 55,44 $'a (FDA kataliz\u00f6r y\u00fckseli\u015fi)<\/li> <\/ul> <p>En dramatik hareket Temmuz sonu ile A\u011fustos aras\u0131nda ger\u00e7ekle\u015fti; hisse yakla\u015f\u0131k 13,59 $'dan 55 $'\u0131n \u00fczerine \u00e7\u0131karak <strong>alt\u0131 haftadan k\u0131sa s\u00fcrede %300'den fazla kazan\u00e7<\/strong> sa\u011flad\u0131. Bu kademeli bir b\u00fcy\u00fcme de\u011fildi; klinik ba\u015far\u0131 ve d\u00fczenleyici d\u00f6n\u00fcm noktalar\u0131 taraf\u0131ndan tetiklenen dik bir t\u0131rman\u0131\u015ft\u0131.<\/p>  <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <ul> <li><strong>2025 (Y\u0131l Sonu)<\/strong>: 60-68 $<br\/> Mevcut momentum ve 4. \u00e7eyrek FDA ba\u015fvuru ilerlemesine dayanarak, CELC yeni zirveleri test edebilir. Ortalama analist hedefi 53,60 $ (<a href=\"https:\/\/stockanalysis.com\/stocks\/celc\/forecast\/\">StockAnalysis<\/a>) civar\u0131nda, ancak son y\u00fckseltmeler 66-79 $ hedeflerinin ortaya \u00e7\u0131kt\u0131\u011f\u0131n\u0131 g\u00f6steriyor.<\/li> <li><strong>2026<\/strong>: 75-90 $<br\/> Gedatolisib'in 2026'da beklenen FDA onay\u0131n\u0131 almas\u0131 durumunda, ticari lansman \u00f6nemli gelir projeksiyonlar\u0131 ve hisse de\u011fer art\u0131\u015f\u0131 sa\u011flayabilir.<\/li> <li><strong>2028<\/strong>: 110-140 $<br\/> 2028'e kadar, ba\u015far\u0131l\u0131 pazar penetrasyonu ve potansiyel etiket geni\u015flemeleri varsay\u0131larak, Celcuity orta \u00f6l\u00e7ekli bir biyoteknoloji lideri olarak konumlanabilir.<\/li> <li><strong>2030<\/strong>: 160-200 $<br\/> Gedatolisib ve \u00fcr\u00fcn hatt\u0131 geli\u015ftirmede uzun vadeli ba\u015far\u0131, Celcuity'yi sat\u0131n alma hedefi veya ba\u011f\u0131ms\u0131z b\u00fcy\u00fcme ile \u00e7ok milyar dolarl\u0131k bir franchise haline getirebilir.<\/li> <\/ul> <p><strong>Sonu\u00e7<\/strong>: R\u0130SK TOLERANSI Y\u00dcKSEK yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00dc\u00c7L\u00dc ALIM. FDA kataliz\u00f6r\u00fc, onay s\u00fcreci boyunca devam edebilecek bir momentum yaratt\u0131.<\/p>  <h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler:<\/h3> <ul> <li><strong>Klinik Ba\u015far\u0131s\u0131zl\u0131k Riski<\/strong>: Pozitif Faz 3 verilerine ra\u011fmen, FDA ek \u00e7al\u0131\u015fmalar talep edebilir veya ba\u015fvuruyu reddedebilir<\/li> <li><strong>Biyoteknoloji Volatilitesi<\/strong>: %45,14 volatilite derecesi, vah\u015fi fiyat dalgalanmalar\u0131n\u0131n normal oldu\u011fu anlam\u0131na gelir<\/li> <li><strong>D\u00fczenleyici Gecikmeler<\/strong>: FDA inceleme s\u00fcreci beklenenden uzun s\u00fcrebilir<\/li> <li><strong>Rekabet<\/strong>: Geli\u015ftirilmekte olan di\u011fer PI3K inhibit\u00f6rleri pazar pay\u0131n\u0131 zorlayabilir<\/li> <li><strong>Finansman \u0130htiya\u00e7lar\u0131<\/strong>: Hisse senedi teklifleri yoluyla ek sermaye art\u0131r\u0131lmas\u0131 gerekebilir<\/li> <\/ul> <h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar:<\/h3> <ul> <li><strong>FDA \u00c7\u0131\u011f\u0131r A\u00e7an Stat\u00fcs\u00fc<\/strong>: Gedatolisib hem \u00c7\u0131\u011f\u0131r A\u00e7an Tedavi hem de H\u0131zl\u0131 Onay tasar\u0131mlar\u0131na sahip<\/li> <li><strong>Faz 3 Ba\u015far\u0131s\u0131<\/strong>: Hastal\u0131k ilerlemesinde %76 risk azalt\u0131m\u0131 ola\u011fan\u00fcst\u00fc veri<\/li> <li><strong>Pazar \u0130htiyac\u0131<\/strong>: HR+\/HER2- meme kanseri \u00f6nemli kar\u015f\u0131lanmam\u0131\u015f t\u0131bbi ihtiya\u00e7<\/li> <li><strong>Analist Deste\u011fi<\/strong>: Y\u00fckselen fiyat hedefleriyle G\u00fc\u00e7l\u00fc Al\u0131m konsens\u00fcs\u00fc<\/li> <li><strong>Kurumsal \u0130lgi<\/strong>: Artan Wall Street kapsam\u0131 ve yat\u0131r\u0131mc\u0131 ilgisi<\/li> <\/ul>  <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Gece uykunuzu ka\u00e7\u0131rmayacak bir pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fc ile ba\u015flay\u0131n\u2014biyoteknoloji volatil bir aland\u0131r<\/li> <li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: Pozisyonunuzu tek seferde de\u011fil, birka\u00e7 hafta i\u00e7inde kademeli olarak olu\u015fturmay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/li> <li><strong>13 Kas\u0131m \u0130\u00e7in Uyar\u0131 Kurun<\/strong>: 3. \u00e7eyrek kazan\u00e7lar\u0131 bir sonraki b\u00fcy\u00fck kataliz\u00f6r\u00fc sa\u011flayabilir<\/li> <li><strong>\u00c7\u0131k\u0131\u015f Stratejisi Belirleyin<\/strong>: Al\u0131m \u00f6ncesi kar alma ve zarar durdurma seviyelerinizi bilin<\/li> <li><em>Mizahi deneyimli tavsiye<\/em>: \"CELC ticareti bir roket s\u00fcrmek gibidir\u2014heyecan verici, ama para\u015f\u00fct\u00fcn\u00fcz\u00fc yan\u0131n\u0131za ald\u0131\u011f\u0131n\u0131zdan emin olun!\"<\/li> <\/ol>  <h2>\u2705 Celcuity Inc. (CELC) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table border=\"1\" cellpadding=\"5\" cellspacing=\"0\"> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir Ticaret Platformu Se\u00e7in<\/td><td>NASDAQ hisselerini sunan ve makul \u00fccretlere sahip oldu\u011fundan emin olun<\/td><\/tr> <tr><td>2<\/td><td>Hesab\u0131n\u0131z\u0131 A\u00e7\u0131n ve Fonlay\u0131n<\/td><td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>3<\/td><td>\"CELC\" Aray\u0131n<\/td><td>Sadece \u015firket ad\u0131 de\u011fil, sembol\u00fc kullan\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td><td>Giri\u015f fiyat\u0131n\u0131z\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td><\/tr> <tr><td>5<\/td><td>\u0130nceleyin ve Onaylay\u0131n<\/td><td>Emir detaylar\u0131n\u0131 iki kez kontrol edin<\/td><\/tr> <tr><td>6<\/td><td>Fiyat Uyar\u0131lar\u0131 Kurun<\/td><td>\u00d6nemli haberler ve fiyat hareketlerini takip edin<\/td><\/tr> <tr><td>7<\/td><td>Yat\u0131r\u0131m\u0131n\u0131z\u0131 Takip Edin<\/td><td>Portf\u00f6y takip ara\u00e7lar\u0131 kullanarak g\u00fcncel kal\u0131n<\/td><\/tr> <tr><td>8<\/td><td>\u00c7\u0131k\u0131\u015f Stratejinizi Planlay\u0131n<\/td><td>K\u00e2r al\u0131m ve zarar durdurma zamanlar\u0131n\u0131 \u00f6nceden belirleyin<\/td><\/tr> <\/tbody> <\/table>  <h2>\ud83d\udca1 Neden Pocket Option Yeni CELC Yat\u0131r\u0131mc\u0131lar\u0131 \u0130\u00e7in Uygun?<\/h2> <p>Celcuity'ye yat\u0131r\u0131m yapmak isteyenler i\u00e7in Pocket Option, ba\u015flamay\u0131 kolayla\u015ft\u0131ran birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>Sadece 5 $ minimum depozito<\/strong>\u2014CELC ile stratejileri \u00f6nemli risk olmadan test etmek i\u00e7in m\u00fckemmel<\/li> <li><strong>\u015eim\u015fek h\u0131z\u0131nda do\u011frulama<\/strong>\u2014basit belge y\u00fcklemesiyle dakikalar i\u00e7inde ticarete ba\u015flay\u0131n<\/li> <li><strong>\u00c7oklu para \u00e7ekme se\u00e7enekleri<\/strong>\u2014k\u00e2rlar\u0131n\u0131za \u00e7e\u015fitli uygun y\u00f6ntemlerle eri\u015fin<\/li> <li><strong>Kullan\u0131c\u0131 dostu platform<\/strong>\u2014biyoteknoloji yat\u0131r\u0131mlar\u0131nda yeni ba\u015flayanlar i\u00e7in ideal<\/li> <\/ul> <p>Platformun d\u00fc\u015f\u00fck giri\u015f engeli, b\u00fcy\u00fck sermaye taahh\u00fcd\u00fc olmadan CELC gibi y\u00fcksek potansiyelli hisselere maruz kalmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in idealdir.<\/p>  <h2>\ud83c\udf0d 2025'te Celcuity: Onkolojinin Y\u00fckselen Y\u0131ld\u0131z\u0131<\/h2> <p>Celcuity Inc., kanser hastalar\u0131 i\u00e7in hedefe y\u00f6nelik tedaviler geli\u015ftirmeye odaklanan klinik a\u015famadaki bir biyoteknoloji \u015firketidir. \u00d6nc\u00fc ila\u00e7 aday\u0131 gedatolisib, PI3K\/AKT\/mTOR yolunu kapsaml\u0131 \u015fekilde bloke eden g\u00fc\u00e7l\u00fc bir pan-PI3K ve mTORC1\/2 inhibit\u00f6r\u00fcd\u00fcr (<a href=\"https:\/\/ir.celcuity.com\">\u015eirket Web Sitesi<\/a>).<\/p> <p>\u015eirketin \u00e7\u0131\u011f\u0131r a\u00e7an Faz 3 VIKTORIA-1 denemesi e\u015fi benzeri g\u00f6r\u00fclmemi\u015f sonu\u00e7lar g\u00f6sterdi: gedatolisib bazl\u0131 rejimler, standart bak\u0131ma k\u0131yasla hastal\u0131k ilerlemesi riskini %76 oran\u0131nda azaltt\u0131 ve medyan progresyonsuz sa\u011fkal\u0131m 2,0 aydan 9,3 aya y\u00fckseldi (<a href=\"https:\/\/www.quiverquant.com\/news\/Celcuity+Inc.+Announces+FDA+Acceptance+of+New+Drug+Application+for+Gedatolisib+in+Advanced+Breast+Cancer+Review+Program\">D\u00fczenleyici Dosya<\/a>).<\/p> <p><strong>2025 \u0130\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: Celcuity CEO'su Brian Sullivan, \u015firketi e\u015finin meme kanseri te\u015fhisinden sonra kurdu\u2014bu sadece ba\u015fka bir biyoteknoloji hikayesi de\u011fil, \u015fimdi d\u00fcnya \u00e7ap\u0131nda hastalara potansiyel olarak hayat kurtaran ila\u00e7lar sunan ki\u015fisel bir misyondur.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 G\u00fcncel Hisse Fiyat\u0131 ve Kritik Tarihler<\/h2>\n<p>29 A\u011fustos 2025 itibar\u0131yla Celcuity Inc. (CELC), NASDAQ&#8217;da <strong>54,60 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>13 Kas\u0131m 2025<\/strong> kesinlikle kritik\u2014Celcuity&#8217;nin 3. \u00e7eyrek kazan\u00e7lar\u0131n\u0131 a\u00e7\u0131klayaca\u011f\u0131 tarih. Tarihsel olarak, bu raporlar fiyatlar\u0131 dramatik \u015fekilde hareket ettirmi\u015ftir.<\/p>\n<p><strong>A\u011fustos 2025&#8217;te FDA Haberlerinin CELC Hissesini Nas\u0131l Hareket Ettirdi\u011fi<\/strong><br \/> Gedatolisib&#8217;in Yeni \u0130la\u00e7 Ba\u015fvurusunun FDA taraf\u0131ndan kabul edilmesi b\u00fcy\u00fck yank\u0131 yaratt\u0131. 28 A\u011fustos 2025&#8217;te CELC, <strong>%10,69 art\u0131\u015fla 55,30 $<\/strong> seviyesine y\u00fckseldi ve 52 haftal\u0131k en y\u00fcksek seviye olan 55,44 $&#8217;a ula\u015ft\u0131 (<a href=\"https:\/\/www.ainvest.com\/news\/celcuity-soars-9-6-record-high-analysts-split-sustainability-2508\/\">AInvest Raporu<\/a>). Bu sadece s\u0131radan bir s\u0131\u00e7rama de\u011fildi\u2014yat\u0131r\u0131mc\u0131lar\u0131 heyecanland\u0131ran <strong>y\u0131lba\u015f\u0131ndan bu yana %210&#8217;luk kazanc\u0131n<\/strong> doruk noktas\u0131yd\u0131.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu: \u0130stikrarl\u0131dan Muhte\u015feme<\/h2>\n<p>Celcuity&#8217;nin hissesi \u015eubat 2025&#8217;ten beri muazzam bir y\u00fckseli\u015f g\u00f6sterdi:<\/p>\n<ul>\n<li><strong>\u015eubat 2025<\/strong>: ~15-18 $ (istikrarl\u0131 klinik ilerleme)<\/li>\n<li><strong>Nisan 2025<\/strong>: ~22-25 $ (Faz 3 veri beklentisi)<\/li>\n<li><strong>Haziran 2025<\/strong>: ~35-40 $ (pozitif deneme s\u00f6ylentileri)<\/li>\n<li><strong>Temmuz 2025<\/strong>: 13,59 $&#8217;dan 50+ $ aral\u0131\u011f\u0131na (patlay\u0131c\u0131 b\u00fcy\u00fcme)<\/li>\n<li><strong>A\u011fustos 2025<\/strong>: 49,96 $&#8217;dan 55,44 $&#8217;a (FDA kataliz\u00f6r y\u00fckseli\u015fi)<\/li>\n<\/ul>\n<p>En dramatik hareket Temmuz sonu ile A\u011fustos aras\u0131nda ger\u00e7ekle\u015fti; hisse yakla\u015f\u0131k 13,59 $&#8217;dan 55 $&#8217;\u0131n \u00fczerine \u00e7\u0131karak <strong>alt\u0131 haftadan k\u0131sa s\u00fcrede %300&#8217;den fazla kazan\u00e7<\/strong> sa\u011flad\u0131. Bu kademeli bir b\u00fcy\u00fcme de\u011fildi; klinik ba\u015far\u0131 ve d\u00fczenleyici d\u00f6n\u00fcm noktalar\u0131 taraf\u0131ndan tetiklenen dik bir t\u0131rman\u0131\u015ft\u0131.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<ul>\n<li><strong>2025 (Y\u0131l Sonu)<\/strong>: 60-68 $<br \/> Mevcut momentum ve 4. \u00e7eyrek FDA ba\u015fvuru ilerlemesine dayanarak, CELC yeni zirveleri test edebilir. Ortalama analist hedefi 53,60 $ (<a href=\"https:\/\/stockanalysis.com\/stocks\/celc\/forecast\/\">StockAnalysis<\/a>) civar\u0131nda, ancak son y\u00fckseltmeler 66-79 $ hedeflerinin ortaya \u00e7\u0131kt\u0131\u011f\u0131n\u0131 g\u00f6steriyor.<\/li>\n<li><strong>2026<\/strong>: 75-90 $<br \/> Gedatolisib&#8217;in 2026&#8217;da beklenen FDA onay\u0131n\u0131 almas\u0131 durumunda, ticari lansman \u00f6nemli gelir projeksiyonlar\u0131 ve hisse de\u011fer art\u0131\u015f\u0131 sa\u011flayabilir.<\/li>\n<li><strong>2028<\/strong>: 110-140 $<br \/> 2028&#8217;e kadar, ba\u015far\u0131l\u0131 pazar penetrasyonu ve potansiyel etiket geni\u015flemeleri varsay\u0131larak, Celcuity orta \u00f6l\u00e7ekli bir biyoteknoloji lideri olarak konumlanabilir.<\/li>\n<li><strong>2030<\/strong>: 160-200 $<br \/> Gedatolisib ve \u00fcr\u00fcn hatt\u0131 geli\u015ftirmede uzun vadeli ba\u015far\u0131, Celcuity&#8217;yi sat\u0131n alma hedefi veya ba\u011f\u0131ms\u0131z b\u00fcy\u00fcme ile \u00e7ok milyar dolarl\u0131k bir franchise haline getirebilir.<\/li>\n<\/ul>\n<p><strong>Sonu\u00e7<\/strong>: R\u0130SK TOLERANSI Y\u00dcKSEK yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00dc\u00c7L\u00dc ALIM. FDA kataliz\u00f6r\u00fc, onay s\u00fcreci boyunca devam edebilecek bir momentum yaratt\u0131.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler:<\/h3>\n<ul>\n<li><strong>Klinik Ba\u015far\u0131s\u0131zl\u0131k Riski<\/strong>: Pozitif Faz 3 verilerine ra\u011fmen, FDA ek \u00e7al\u0131\u015fmalar talep edebilir veya ba\u015fvuruyu reddedebilir<\/li>\n<li><strong>Biyoteknoloji Volatilitesi<\/strong>: %45,14 volatilite derecesi, vah\u015fi fiyat dalgalanmalar\u0131n\u0131n normal oldu\u011fu anlam\u0131na gelir<\/li>\n<li><strong>D\u00fczenleyici Gecikmeler<\/strong>: FDA inceleme s\u00fcreci beklenenden uzun s\u00fcrebilir<\/li>\n<li><strong>Rekabet<\/strong>: Geli\u015ftirilmekte olan di\u011fer PI3K inhibit\u00f6rleri pazar pay\u0131n\u0131 zorlayabilir<\/li>\n<li><strong>Finansman \u0130htiya\u00e7lar\u0131<\/strong>: Hisse senedi teklifleri yoluyla ek sermaye art\u0131r\u0131lmas\u0131 gerekebilir<\/li>\n<\/ul>\n<h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar:<\/h3>\n<ul>\n<li><strong>FDA \u00c7\u0131\u011f\u0131r A\u00e7an Stat\u00fcs\u00fc<\/strong>: Gedatolisib hem \u00c7\u0131\u011f\u0131r A\u00e7an Tedavi hem de H\u0131zl\u0131 Onay tasar\u0131mlar\u0131na sahip<\/li>\n<li><strong>Faz 3 Ba\u015far\u0131s\u0131<\/strong>: Hastal\u0131k ilerlemesinde %76 risk azalt\u0131m\u0131 ola\u011fan\u00fcst\u00fc veri<\/li>\n<li><strong>Pazar \u0130htiyac\u0131<\/strong>: HR+\/HER2- meme kanseri \u00f6nemli kar\u015f\u0131lanmam\u0131\u015f t\u0131bbi ihtiya\u00e7<\/li>\n<li><strong>Analist Deste\u011fi<\/strong>: Y\u00fckselen fiyat hedefleriyle G\u00fc\u00e7l\u00fc Al\u0131m konsens\u00fcs\u00fc<\/li>\n<li><strong>Kurumsal \u0130lgi<\/strong>: Artan Wall Street kapsam\u0131 ve yat\u0131r\u0131mc\u0131 ilgisi<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Gece uykunuzu ka\u00e7\u0131rmayacak bir pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fc ile ba\u015flay\u0131n\u2014biyoteknoloji volatil bir aland\u0131r<\/li>\n<li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: Pozisyonunuzu tek seferde de\u011fil, birka\u00e7 hafta i\u00e7inde kademeli olarak olu\u015fturmay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/li>\n<li><strong>13 Kas\u0131m \u0130\u00e7in Uyar\u0131 Kurun<\/strong>: 3. \u00e7eyrek kazan\u00e7lar\u0131 bir sonraki b\u00fcy\u00fck kataliz\u00f6r\u00fc sa\u011flayabilir<\/li>\n<li><strong>\u00c7\u0131k\u0131\u015f Stratejisi Belirleyin<\/strong>: Al\u0131m \u00f6ncesi kar alma ve zarar durdurma seviyelerinizi bilin<\/li>\n<li><em>Mizahi deneyimli tavsiye<\/em>: &#8220;CELC ticareti bir roket s\u00fcrmek gibidir\u2014heyecan verici, ama para\u015f\u00fct\u00fcn\u00fcz\u00fc yan\u0131n\u0131za ald\u0131\u011f\u0131n\u0131zdan emin olun!&#8221;<\/li>\n<\/ol>\n<h2>\u2705 Celcuity Inc. (CELC) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table border=\"1\" cellpadding=\"5\" cellspacing=\"0\">\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir Ticaret Platformu Se\u00e7in<\/td>\n<td>NASDAQ hisselerini sunan ve makul \u00fccretlere sahip oldu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesab\u0131n\u0131z\u0131 A\u00e7\u0131n ve Fonlay\u0131n<\/td>\n<td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;CELC&#8221; Aray\u0131n<\/td>\n<td>Sadece \u015firket ad\u0131 de\u011fil, sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td>\n<td>Giri\u015f fiyat\u0131n\u0131z\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u0130nceleyin ve Onaylay\u0131n<\/td>\n<td>Emir detaylar\u0131n\u0131 iki kez kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Fiyat Uyar\u0131lar\u0131 Kurun<\/td>\n<td>\u00d6nemli haberler ve fiyat hareketlerini takip edin<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Yat\u0131r\u0131m\u0131n\u0131z\u0131 Takip Edin<\/td>\n<td>Portf\u00f6y takip ara\u00e7lar\u0131 kullanarak g\u00fcncel kal\u0131n<\/td>\n<\/tr>\n<tr>\n<td>8<\/td>\n<td>\u00c7\u0131k\u0131\u015f Stratejinizi Planlay\u0131n<\/td>\n<td>K\u00e2r al\u0131m ve zarar durdurma zamanlar\u0131n\u0131 \u00f6nceden belirleyin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Neden Pocket Option Yeni CELC Yat\u0131r\u0131mc\u0131lar\u0131 \u0130\u00e7in Uygun?<\/h2>\n<p>Celcuity&#8217;ye yat\u0131r\u0131m yapmak isteyenler i\u00e7in Pocket Option, ba\u015flamay\u0131 kolayla\u015ft\u0131ran birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>Sadece 5 $ minimum depozito<\/strong>\u2014CELC ile stratejileri \u00f6nemli risk olmadan test etmek i\u00e7in m\u00fckemmel<\/li>\n<li><strong>\u015eim\u015fek h\u0131z\u0131nda do\u011frulama<\/strong>\u2014basit belge y\u00fcklemesiyle dakikalar i\u00e7inde ticarete ba\u015flay\u0131n<\/li>\n<li><strong>\u00c7oklu para \u00e7ekme se\u00e7enekleri<\/strong>\u2014k\u00e2rlar\u0131n\u0131za \u00e7e\u015fitli uygun y\u00f6ntemlerle eri\u015fin<\/li>\n<li><strong>Kullan\u0131c\u0131 dostu platform<\/strong>\u2014biyoteknoloji yat\u0131r\u0131mlar\u0131nda yeni ba\u015flayanlar i\u00e7in ideal<\/li>\n<\/ul>\n<p>Platformun d\u00fc\u015f\u00fck giri\u015f engeli, b\u00fcy\u00fck sermaye taahh\u00fcd\u00fc olmadan CELC gibi y\u00fcksek potansiyelli hisselere maruz kalmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in idealdir.<\/p>\n<h2>\ud83c\udf0d 2025&#8217;te Celcuity: Onkolojinin Y\u00fckselen Y\u0131ld\u0131z\u0131<\/h2>\n<p>Celcuity Inc., kanser hastalar\u0131 i\u00e7in hedefe y\u00f6nelik tedaviler geli\u015ftirmeye odaklanan klinik a\u015famadaki bir biyoteknoloji \u015firketidir. \u00d6nc\u00fc ila\u00e7 aday\u0131 gedatolisib, PI3K\/AKT\/mTOR yolunu kapsaml\u0131 \u015fekilde bloke eden g\u00fc\u00e7l\u00fc bir pan-PI3K ve mTORC1\/2 inhibit\u00f6r\u00fcd\u00fcr (<a href=\"https:\/\/ir.celcuity.com\">\u015eirket Web Sitesi<\/a>).<\/p>\n<p>\u015eirketin \u00e7\u0131\u011f\u0131r a\u00e7an Faz 3 VIKTORIA-1 denemesi e\u015fi benzeri g\u00f6r\u00fclmemi\u015f sonu\u00e7lar g\u00f6sterdi: gedatolisib bazl\u0131 rejimler, standart bak\u0131ma k\u0131yasla hastal\u0131k ilerlemesi riskini %76 oran\u0131nda azaltt\u0131 ve medyan progresyonsuz sa\u011fkal\u0131m 2,0 aydan 9,3 aya y\u00fckseldi (<a href=\"https:\/\/www.quiverquant.com\/news\/Celcuity+Inc.+Announces+FDA+Acceptance+of+New+Drug+Application+for+Gedatolisib+in+Advanced+Breast+Cancer+Review+Program\">D\u00fczenleyici Dosya<\/a>).<\/p>\n<p><strong>2025 \u0130\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: Celcuity CEO&#8217;su Brian Sullivan, \u015firketi e\u015finin meme kanseri te\u015fhisinden sonra kurdu\u2014bu sadece ba\u015fka bir biyoteknoloji hikayesi de\u011fil, \u015fimdi d\u00fcnya \u00e7ap\u0131nda hastalara potansiyel olarak hayat kurtaran ila\u00e7lar sunan ki\u015fisel bir misyondur.<\/p>\n"},"faq":[{"question":"Celcuity Inc. (CELC) hisseleri nas\u0131l al\u0131n\u0131r?","answer":"Bir arac\u0131 kurumda hesap a\u00e7arak, CELC sembol\u00fc ile hisse senedini aray\u0131n, limit emir kullanarak uygun fiyattan al\u0131m yapabilirsiniz."},{"question":"Gedatolisib nedir ve neden \u00f6nemlidir?","answer":"Gedatolisib, Celcuity'nin meme kanseri tedavisinde kulland\u0131\u011f\u0131 g\u00fc\u00e7l\u00fc bir PI3K ve mTOR inhibit\u00f6r\u00fcd\u00fcr ve hastal\u0131k ilerlemesini %76 oran\u0131nda azaltm\u0131\u015ft\u0131r."},{"question":"FDA onay\u0131 Celcuity hisselerini nas\u0131l etkiler?","answer":"FDA onay\u0131, hisse fiyat\u0131nda \u00f6nemli art\u0131\u015flara yol a\u00e7abilir \u00e7\u00fcnk\u00fc bu, ilac\u0131n pazara \u00e7\u0131k\u0131\u015f\u0131n\u0131 ve gelir potansiyelini art\u0131r\u0131r."},{"question":"Yat\u0131r\u0131m yaparken hangi riskler g\u00f6z \u00f6n\u00fcnde bulundurulmal\u0131?","answer":"Klinik ba\u015far\u0131s\u0131zl\u0131k, d\u00fczenleyici gecikmeler, piyasa volatilitesi ve rekabet gibi riskler yat\u0131r\u0131m karar\u0131nda dikkate al\u0131nmal\u0131d\u0131r."},{"question":"Yeni ba\u015flayanlar i\u00e7in yat\u0131r\u0131m stratejisi nedir?","answer":"K\u00fc\u00e7\u00fck ba\u015flay\u0131n, dolar maliyet ortalamas\u0131 yap\u0131n, \u00f6nemli tarihleri takip edin ve \u00f6nceden \u00e7\u0131k\u0131\u015f stratejisi belirleyin."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Celcuity Inc. (CELC) hisseleri nas\u0131l al\u0131n\u0131r?","answer":"Bir arac\u0131 kurumda hesap a\u00e7arak, CELC sembol\u00fc ile hisse senedini aray\u0131n, limit emir kullanarak uygun fiyattan al\u0131m yapabilirsiniz."},{"question":"Gedatolisib nedir ve neden \u00f6nemlidir?","answer":"Gedatolisib, Celcuity'nin meme kanseri tedavisinde kulland\u0131\u011f\u0131 g\u00fc\u00e7l\u00fc bir PI3K ve mTOR inhibit\u00f6r\u00fcd\u00fcr ve hastal\u0131k ilerlemesini %76 oran\u0131nda azaltm\u0131\u015ft\u0131r."},{"question":"FDA onay\u0131 Celcuity hisselerini nas\u0131l etkiler?","answer":"FDA onay\u0131, hisse fiyat\u0131nda \u00f6nemli art\u0131\u015flara yol a\u00e7abilir \u00e7\u00fcnk\u00fc bu, ilac\u0131n pazara \u00e7\u0131k\u0131\u015f\u0131n\u0131 ve gelir potansiyelini art\u0131r\u0131r."},{"question":"Yat\u0131r\u0131m yaparken hangi riskler g\u00f6z \u00f6n\u00fcnde bulundurulmal\u0131?","answer":"Klinik ba\u015far\u0131s\u0131zl\u0131k, d\u00fczenleyici gecikmeler, piyasa volatilitesi ve rekabet gibi riskler yat\u0131r\u0131m karar\u0131nda dikkate al\u0131nmal\u0131d\u0131r."},{"question":"Yeni ba\u015flayanlar i\u00e7in yat\u0131r\u0131m stratejisi nedir?","answer":"K\u00fc\u00e7\u00fck ba\u015flay\u0131n, dolar maliyet ortalamas\u0131 yap\u0131n, \u00f6nemli tarihleri takip edin ve \u00f6nceden \u00e7\u0131k\u0131\u015f stratejisi belirleyin."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Celcuity Inc. (CELC) Hisseleri Nas\u0131l Al\u0131n\u0131r - Celcuity Inc. (CELC) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celcuity\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Celcuity Inc. (CELC) Hisseleri Nas\u0131l Al\u0131n\u0131r - Celcuity Inc. (CELC) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celcuity\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-29T10:27:58+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celcuity\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celcuity\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Celcuity Inc. (CELC) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Celcuity Inc. (CELC) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-29T10:27:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celcuity\/\"},\"wordCount\":19,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celcuity\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals12.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celcuity\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celcuity\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celcuity\/\",\"name\":\"Celcuity Inc. (CELC) Hisseleri Nas\u0131l Al\u0131n\u0131r - Celcuity Inc. (CELC) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celcuity\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celcuity\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals12.webp\",\"datePublished\":\"2025-08-29T10:27:58+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celcuity\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celcuity\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celcuity\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals12.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals12.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celcuity\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Celcuity Inc. (CELC) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Celcuity Inc. (CELC) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Celcuity Inc. (CELC) Hisseleri Nas\u0131l Al\u0131n\u0131r - Celcuity Inc. (CELC) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celcuity\/","og_locale":"tr_TR","og_type":"article","og_title":"Celcuity Inc. (CELC) Hisseleri Nas\u0131l Al\u0131n\u0131r - Celcuity Inc. (CELC) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celcuity\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-29T10:27:58+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celcuity\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celcuity\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Celcuity Inc. (CELC) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Celcuity Inc. (CELC) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-29T10:27:58+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celcuity\/"},"wordCount":19,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celcuity\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals12.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celcuity\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celcuity\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celcuity\/","name":"Celcuity Inc. (CELC) Hisseleri Nas\u0131l Al\u0131n\u0131r - Celcuity Inc. (CELC) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celcuity\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celcuity\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals12.webp","datePublished":"2025-08-29T10:27:58+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celcuity\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celcuity\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celcuity\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals12.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals12.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-celcuity\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Celcuity Inc. (CELC) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Celcuity Inc. (CELC) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":357382,"slug":"how-to-buy-celcuity","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Celcuity Inc. (CELC) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Celcuity Inc. (CELC)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-celcuity\/"},"pt_AA":{"locale":"pt_AA","id":357384,"slug":"how-to-buy-celcuity","post_title":"Como comprar a\u00e7\u00f5es da Celcuity Inc. (CELC) - Investimento em a\u00e7\u00f5es da Celcuity Inc. (CELC)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-celcuity\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/357380","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=357380"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/357380\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334090"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=357380"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=357380"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=357380"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}